A Randomized, Double-Blinded, Active Controlled COVID-19 Study to Evaluate The Safety, Tolerability, And Immunogenicity Of Different Doses Of VLA2001 Vaccine, In Children (≥2 To <12 Years)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VLA 2001 (Primary) ; Aluminium hydroxide; Meningococcal vaccine groups A C Y W-135 conjugate
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Valneva

03 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
09 Aug 2022 Planned End Date changed from 30 Apr 2025 to 30 Aug 2025.
09 Aug 2022 Planned primary completion date changed from 31 Mar 2023 to 31 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com